Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.505
Filtrer
2.
Front Endocrinol (Lausanne) ; 15: 1384984, 2024.
Article de Anglais | MEDLINE | ID: mdl-38854687

RÉSUMÉ

Introduction: With the increasing prevalence of type 2 diabetes mellitus (T2DM), there is an urgent need to discover effective therapeutic targets for this complex condition. Coding and non-coding RNAs, with traditional biochemical parameters, have shown promise as viable targets for therapy. Machine learning (ML) techniques have emerged as powerful tools for predicting drug responses. Method: In this study, we developed an ML-based model to identify the most influential features for drug response in the treatment of type 2 diabetes using three medicinal plant-based drugs (Rosavin, Caffeic acid, and Isorhamnetin), and a probiotics drug (Z-biotic), at different doses. A hundred rats were randomly assigned to ten groups, including a normal group, a streptozotocin-induced diabetic group, and eight treated groups. Serum samples were collected for biochemical analysis, while liver tissues (L) and adipose tissues (A) underwent histopathological examination and molecular biomarker extraction using quantitative PCR. Utilizing five machine learning algorithms, we integrated 32 molecular features and 12 biochemical features to select the most predictive targets for each model and the combined model. Results and discussion: Our results indicated that high doses of the selected drugs effectively mitigated liver inflammation, reduced insulin resistance, and improved lipid profiles and renal function biomarkers. The machine learning model identified 13 molecular features, 10 biochemical features, and 20 combined features with an accuracy of 80% and AUC (0.894, 0.93, and 0.896), respectively. This study presents an ML model that accurately identifies effective therapeutic targets implicated in the molecular pathways associated with T2DM pathogenesis.


Sujet(s)
Diabète expérimental , Diabète de type 2 , Apprentissage machine , Animaux , Diabète de type 2/traitement médicamenteux , Diabète de type 2/métabolisme , Rats , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Mâle , Hypoglycémiants/usage thérapeutique , Hypoglycémiants/pharmacologie , Rat Sprague-Dawley , Marqueurs biologiques , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Insulinorésistance , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Acides caféiques
3.
Vet Q ; 44(1): 1-14, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-38943615

RÉSUMÉ

Background: Mistletoe is an herb that grows on duku plants (Lancium demosticum) and is known as benalu duku (BD) in Indonesia. It is predicted to have benefits such as anticancer or antiviral properties, and it is also thought to have anti-diabetic pharmacological activity. Quercetin-like compounds (QLCs) are secondary metabolites with antidiabetic activity that are expected to lower blood sugar levels in animals after oral administration.Objective: This study aimed to analyze the ability of QLCs to reduce random blood sugar levels using experimental animals as clinical models.Material and methods: The research method used was exploratory, which used a before-after test model, and observations were made on the random blood sugar levels after treatment. Secondary metabolites were extracted from BD leaves, which were then screened. Diabetes was induced in 30 rats (Rattus norvegicus) by the administration of streptozotocin at 0.045 mg/g body weight daily for 2 days. The antidiabetic effects of the secondary metabolite at doses of 0.5 mg/kg body weight (twice a day) when administered orally for up to 5 days were tested in diabetic rats. The random sugar levels (mg/dL) were measured using a One Touch Ultra Plus medical device for observation of randomized blood sugar levels. Results and novelty: The results revealed that the secondary metabolite, as an analyte from the BD leaf extract, can significantly reduce random blood sugar levels.Conclusion: The secondary metabolite extracted from BD, could be used to treat diabetes in rats.


Sujet(s)
Glycémie , Diabète expérimental , Hypoglycémiants , Extraits de plantes , Quercétine , Animaux , Diabète expérimental/traitement médicamenteux , Diabète expérimental/sang , Rats , Hypoglycémiants/pharmacologie , Hypoglycémiants/usage thérapeutique , Hypoglycémiants/administration et posologie , Quercétine/pharmacologie , Quercétine/analogues et dérivés , Quercétine/usage thérapeutique , Glycémie/analyse , Glycémie/effets des médicaments et des substances chimiques , Mâle , Extraits de plantes/pharmacologie , Extraits de plantes/administration et posologie , Gui/composition chimique , Administration par voie orale , Feuilles de plante/composition chimique
4.
Int Immunopharmacol ; 134: 112240, 2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38744177

RÉSUMÉ

The mounting evidence of valproate-induced testicular damage in clinical settings is alarming, especially for men taking valproate (VPA) for long-term or at high doses. Both donepezil (DON) and quercetin (QUE) have promising antioxidant, anti-inflammatory, and anti-apoptotic effects. Therefore, this study aimed to determine whether DON, QUE, and their combination could mitigate VPA-induced testicular toxicity and unravel the mechanisms underlying their protective effect. In this study, male albino rats were randomly categorized into six equal groups: control, VPA (500 mg/kg, I.P., for 14 days), DON (3 and 5 mg/kg), QUE (50 mg/kg), and DON 3 + QUE combination groups. The DON and QUE treatments were administered orally for 7 consecutive days before VPA administration and then concomitantly with VPA for 14 days. VPA administration disrupted testicular function by altering testicular architecture, ultrastructure, reducing sperm count, viability, and serum testosterone levels. Additionally, VPA triggered oxidative damage, inflammatory, and apoptotic processes and suppressed the AMPK/SIRT1/PGC-1α signaling cascade. Pretreatment with DON, QUE, and their combination significantly alleviated histological and ultrastructure damage caused by VPA and increased the serum testosterone level, sperm count, and viability. They also suppressed the oxidative stress by reducing testicular MDA content and elevating SOD activity. In addition, they reduced the inflammatory response by suppressing IL-1ß level, NF-κB, and the p38-MAPK expression as well as inhibiting apoptosis by diminishing caspase-3 and increasing Bcl-2 expression. These novel protective effects were mediated by upregulating AMPK/SIRT1/PGC-1α signaling cascade. In conclusion, these findings suggest that DON, QUE, and their combination possess potent protective effects against VPA-induced testicular toxicity.


Sujet(s)
Apoptose , Donépézil , Interleukine-1 bêta , Facteur de transcription NF-kappa B , Stress oxydatif , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes , Quercétine , Transduction du signal , Sirtuine-1 , Testicule , Acide valproïque , Mâle , Animaux , Sirtuine-1/métabolisme , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Stress oxydatif/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes/métabolisme , Testicule/effets des médicaments et des substances chimiques , Testicule/anatomopathologie , Testicule/métabolisme , Donépézil/pharmacologie , Donépézil/usage thérapeutique , Rats , Facteur de transcription NF-kappa B/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Interleukine-1 bêta/métabolisme , AMP-Activated Protein Kinases/métabolisme , Antioxydants/pharmacologie , Antioxydants/usage thérapeutique , p38 Mitogen-Activated Protein Kinases/métabolisme , Inflammation/traitement médicamenteux , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique
5.
Mol Biol Rep ; 51(1): 695, 2024 May 25.
Article de Anglais | MEDLINE | ID: mdl-38796674

RÉSUMÉ

Traumatic brain injury (TBI) is a leading cause of disability worldwide, with an estimated annual incidence of 27-69 million. TBI is a severe condition that can lead to high mortality rates and long-term cognitive, behavioral, and physical impairments in young adults. It is a significant public health concern due to the lack of effective treatments available. Quercetin, a natural flavonoid found in various fruits and vegetables, has demonstrated therapeutic potential with anti-inflammatory, antioxidant, and neuroprotective properties. Recently, some evidence has accentuated the ameliorating effects of quercetin on TBI. This review discusses quercetin's ability to reduce TBI-related damage by regulating many cellular and molecular pathways. Quercetin in vitro and in vivo studies exhibit promise in reducing inflammation, oxidative stress, apoptosis, and enhancing cognitive function post-TBI. Further clinical investigation into quercetin's therapeutic potential as a readily available adjuvant in the treatment of TBI is warranted in light of these findings. This review adds to our knowledge of quercetin's potential in treating TBI by clarifying its mechanisms of action.


Sujet(s)
Antioxydants , Lésions traumatiques de l'encéphale , Neuroprotecteurs , Stress oxydatif , Quercétine , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Lésions traumatiques de l'encéphale/traitement médicamenteux , Humains , Animaux , Antioxydants/pharmacologie , Antioxydants/usage thérapeutique , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/usage thérapeutique , Stress oxydatif/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique
6.
Int Immunopharmacol ; 136: 112341, 2024 Jul 30.
Article de Anglais | MEDLINE | ID: mdl-38810309

RÉSUMÉ

BACKGROUND: Osteoporosis (OP) is a common systemic skeletal disorder characterized by an imbalance in bone homeostasis, involving increased osteoclastic bone formation and decreased osteoblastic bone resorption. Quercetin is a plant polyphenol that has been found to exhibit various biological activities, including antioxidant, anti-inflammatory, and antimicrobial effects. Previous studies have demonstrated its potential to improve postmenopausal OP, although the exact mechanism remains unclear. This study aims to investigate the anti-osteoporotic mechanism of quercetin based on the "intestinal flora - short-chain fatty acids (SCFAs) - inflammatory" signaling axis. METHODS: In this study, we established an ovariectomized (OVX)-induced rat model, quercetin intervention and evaluated the effects on rats following antibiotic (ABX) treatment and fecal microbiota transplantation (FMT). After 6 weeks of intervention, the rats were euthanized, and samples from their femur, tibia, lumbar spine, serum, colon and feces were collected, and bone strength, intestinal flora structure, SCFAs levels and cytokine levels were assessed. RESULTS: Quercetin modulates the intestinal flora by increasing potentially probiotic bacteria (i.e., Lactobacillales, Prevotellaceae, and Blautia) and decreasing potentially pathogenic bacteria (Desulfobacterota, Erysipelotrichales, Romboutsia, and Butyricoccaceae). It also increases SCFAs content and reduces colonic permeability by enhancing tight junction proteins (ZO-1, Occludin). Furthermore, quercetin lowers proinflammatory cytokine levels (LPS, IL-1ß, and TNF-α), which enhances bone strength and prevents OVX-induced bone loss. CONCLUSIONS: Quercetin may effectively reduce bone loss in OVX rats via the "intestinal flora - SCFAs - inflammatory" signaling pathway.


Sujet(s)
Acides gras volatils , Microbiome gastro-intestinal , Ovariectomie , Quercétine , Rat Sprague-Dawley , Transduction du signal , Animaux , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Femelle , Acides gras volatils/métabolisme , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Transplantation de microbiote fécal , Ostéoporose/traitement médicamenteux , Modèles animaux de maladie humaine , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique , Humains , Inflammation/traitement médicamenteux
7.
Int Immunopharmacol ; 135: 112318, 2024 Jun 30.
Article de Anglais | MEDLINE | ID: mdl-38795598

RÉSUMÉ

Ferroptosis of intestinal epithelial cells (IECs) had been identified as a key factor in the development of ulcerative colitis (UC). Therefore, targeted inhibition of ferroptosis may provide a new strategy for the treatment of UC. Isorhamnetin (ISO) was an O-methylated flavonol with therapeutic effects on a variety of diseases, such as cardiovascular disease, neurological disorders and tumors. However, the role and mechanism of ISO in ferroptosis and associated colitis were rarely investigated. In this study, we demonstrated that ISO could effectively alleviate intestinal inflammation by inhibiting ferroptosis of IECs in DSS-induced mice. Moreover, our results shown that ISO acted as a potent and common ferroptosis inhibitor in multiple human and murine cell lines. Mechanistically, ISO inhibited ferroptosis independent of its previously reported targets MEK1 and PI3K, but alleviated oxidative stress by targeting and activating NRF2. Furthermore, ISO could also directly chelate iron to hinder ferroptosis. In conclusion, our study indicated that ISO as a novel potential ferroptosis inhibitor, providing a promising therapeutic strategy for ferroptosis-related colitis.


Sujet(s)
Ferroptose , Heme oxygenase-1 , Souris de lignée C57BL , Facteur-2 apparenté à NF-E2 , Quercétine , Transduction du signal , Animaux , Ferroptose/effets des médicaments et des substances chimiques , Facteur-2 apparenté à NF-E2/métabolisme , Quercétine/pharmacologie , Quercétine/analogues et dérivés , Quercétine/usage thérapeutique , Humains , Souris , Heme oxygenase-1/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Colite/traitement médicamenteux , Colite/induit chimiquement , Colite/métabolisme , Sulfate dextran , Fer/métabolisme , Agents chélateurs du fer/pharmacologie , Agents chélateurs du fer/usage thérapeutique , Lignée cellulaire , Mâle , Stress oxydatif/effets des médicaments et des substances chimiques , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/anatomopathologie , Rectocolite hémorragique/induit chimiquement
8.
Iran J Med Sci ; 49(5): 322-331, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38751871

RÉSUMÉ

Background: Cytokine release syndrome (CRS) is the leading cause of mortality in advanced stages of coronavirus patients. This study examined the prophylactic effects of fraxin, quercetin, and a combination of fraxin+quercetin (FQ) on lipopolysaccharide-induced mice. Methods: Sixty mice were divided into six groups (n=10) as follows: control, LPS only, fraxin (120 mg/Kg), quercetin (100 mg/Kg), dexamethasone (5 mg/Kg), and FQ. All treatments were administered intraperitoneally (IP) one hour before induction by LPS (5 mg/Kg) IP injection. Twenty-four hours later, the mice were euthanized. Interleukin one beta (IL-1ß), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were quantified using an enzyme-linked immunosorbent assay (ELISA), and lung and kidney tissues were examined for histopathological alterations. This study was conducted at Al-Nahrain University, Baghdad, Iraq, in 2022. Results: FQ reduced IL-1ß (P<0.001). All treatments significantly suppressed IL-6, fraxin, quercetin, dexamethasone, and FQ, all with P<0.001. The TNF-α level was reduced more with dexamethasone (P<0.001) and quercetin (P<0.001). Histopathological scores were significantly reduced mainly by quercetin and FQ in the lungs with scores of 12.30±0.20 (P=0.093), and 15.70±0.20 (P=0.531), respectively. The scores were 13±0.26 (P=0.074) and 15±0.26 (P=0.222) for quercetin and FQ in the kidneys, respectively. Conclusion: All used treatments reduced proinflammatory cytokine levels and protected against LPS-induced tissue damage.


Sujet(s)
Syndrome de libération de cytokines , Lipopolysaccharides , Quercétine , Animaux , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Souris , Syndrome de libération de cytokines/traitement médicamenteux , Lipopolysaccharides/pharmacologie , Traitements médicamenteux de la COVID-19 , Mâle , COVID-19 , Dexaméthasone/pharmacologie , Dexaméthasone/usage thérapeutique , Interleukine-6/sang , Interleukine-6/analyse , Cytokines/effets des médicaments et des substances chimiques , Interleukine-1 bêta , Facteur de nécrose tumorale alpha , Modèles animaux de maladie humaine , Poumon/effets des médicaments et des substances chimiques , Poumon/anatomopathologie , Coumarines
9.
Autoimmunity ; 57(1): 2350202, 2024 Apr 22.
Article de Anglais | MEDLINE | ID: mdl-38721694

RÉSUMÉ

Yinchenhao Decoction (YCHD) is a classic prescription in traditional Chinese medicine (TCM). It appears to play an important role in anti-inflammation and autoimmunity protection. As one of the key active ingredients in YCHD, quercetin is a novel anti-inflammatory metabolite that exerts protective effects in many autoimmune diseases. However, its role in autoimmune hepatitis (AIH)-related hepatic injury has not been studied. The aim of this study was to reveal the hepatocyte protective mechanism of quercetin. In this study, we used Concanavalin A (Con A) to establish an in vitro hepatocyte injury-associated AIH model. Brl3a hepatocyte injury was induced by the supernatant of J774A.1 cells treated with Con A. We found that quercetin mitigated Con A-induced via macrophage-mediated Brl3a hepatocyte injury. Quercetin administration reduced the levels of alanine transaminase (ALT) and aspartate transaminase (AST) in the supernatant of Con A-treated Brl3a cells and attenuated the infiltration of J774A.1 macrophages induced by Con A. Moreover, quercetin effectively inhibited the expression of proinflammatory cytokines including interleukin-1ß (IL-1ß) by Con A. Furthermore, quercetin decreased hepatocyte apoptosis and ferroptosis levels in the macrophage-induced hepatocyte injury model. In conclusion, our study indicates that quercetin alleviates macrophage-induced hepatocyte damage by reducing the inflammatory response, apoptosis and ferroptosis. Our work suggests that quercetin might be a potential therapeutic strategy for AIH.


Sujet(s)
Anti-inflammatoires , Apoptose , Ferroptose , Hépatocytes , Macrophages , Quercétine , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Animaux , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/métabolisme , Macrophages/métabolisme , Macrophages/effets des médicaments et des substances chimiques , Macrophages/immunologie , Ferroptose/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Souris , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique , Lignée cellulaire , Hépatite auto-immune/traitement médicamenteux , Hépatite auto-immune/immunologie , Hépatite auto-immune/anatomopathologie , Hépatite auto-immune/métabolisme , Hépatite auto-immune/étiologie , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Inflammation/immunologie , Concanavaline A , Cytokines/métabolisme
10.
Int J Mol Sci ; 25(9)2024 May 06.
Article de Anglais | MEDLINE | ID: mdl-38732267

RÉSUMÉ

Osteoporosis, characterized by reduced bone density and increased fracture risk, affects over 200 million people worldwide, predominantly older adults and postmenopausal women. The disruption of the balance between bone-forming osteoblasts and bone-resorbing osteoclasts underlies osteoporosis pathophysiology. Standard treatment includes lifestyle modifications, calcium and vitamin D supplementation and specific drugs that either inhibit osteoclasts or stimulate osteoblasts. However, these treatments have limitations, including side effects and compliance issues. Natural products have emerged as potential osteoporosis therapeutics, but their mechanisms of action remain poorly understood. In this study, we investigate the efficacy of natural compounds in modulating molecular targets relevant to osteoporosis, focusing on the Mitogen-Activated Protein Kinase (MAPK) pathway and the gut microbiome's influence on bone homeostasis. Using an in silico and in vitro methodology, we have identified quercetin as a promising candidate in modulating MAPK activity, offering a potential therapeutic perspective for osteoporosis treatment.


Sujet(s)
Produits biologiques , Remodelage osseux , Ostéoporose , Humains , Remodelage osseux/effets des médicaments et des substances chimiques , Ostéoporose/traitement médicamenteux , Ostéoporose/métabolisme , Produits biologiques/pharmacologie , Produits biologiques/usage thérapeutique , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéoblastes/métabolisme , Os et tissu osseux/métabolisme , Os et tissu osseux/effets des médicaments et des substances chimiques , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Ostéoclastes/métabolisme , Ostéoclastes/effets des médicaments et des substances chimiques , Animaux
11.
Eur J Pharmacol ; 974: 176631, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38692425

RÉSUMÉ

OBJECTIVE: Dasatinib and quercetin (D & Q) have demonstrated promise in improving aged-related pathophysiological dysfunctions in humans and mice. Herein we aimed to ascertain whether the heat stress (HS)-induced cognitive deficits in aged or even young adult male mice can be reduced by D & Q therapy. METHODS: Before the onset of HS, animals were pre-treated with D & Q or placebo for 3 consecutive days every 2 weeks over a 10-week period. Cognitive function, intestinal barrier permeability, and blood-brain barrier permeability were assessed. RESULTS: Compared to the non-HS young adult male mice, the HS young adult male mice or the aged male mice had significantly lesser extents of the exacerbated stress reactions, intestinal barrier disruption, endotoxemia, systemic inflammation and oxidative stress, blood-brain barrier disruption, hippocampal inflammation and oxidative stress, and cognitive deficits evaluated at 7 days post-HS. All the cognitive deficits and other syndromes that occurred in young adult HS mice or in aged HS mice were significantly attenuated by D & Q therapy (P < 0.01). Compared to the young adult HS mice, the aged HS mice had significantly (P < 0.01) higher severity of cognitive deficits and other related syndromes. CONCLUSIONS: First, our data show that aged male mice are more vulnerable to HS-induced cognitive deficits than those of the young adult male mice. Second, we demonstrate that a combination of D and Q therapy attenuates cognitive deficits in heat stressed aged or young adult male mice via broad normalization of the brain-gut-endotoxin axis function.


Sujet(s)
Barrière hémato-encéphalique , Dasatinib , Stress oxydatif , Quercétine , Animaux , Mâle , Dasatinib/pharmacologie , Dasatinib/usage thérapeutique , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Souris , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Barrière hémato-encéphalique/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Vieillissement/effets des médicaments et des substances chimiques , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/étiologie , Réaction de choc thermique/effets des médicaments et des substances chimiques , Perméabilité/effets des médicaments et des substances chimiques , Association de médicaments , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Cognition/effets des médicaments et des substances chimiques
12.
Eur J Pharmacol ; 977: 176666, 2024 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-38797313

RÉSUMÉ

Osteoporosis is a highly prevalent bone metabolic disease in menopause due to estrogen deficiency. Hyperoside is a main compound in Semen cuscutae. Our team previously reported that Semen cuscutae has anti osteoporosis effect on ovariectomized mice by inhibiting bone resorption of osteoclasts. However, it is still unclear whether hyperoside affects osteoclast differentiation and bone resorption, and whether its anti-osteoporosis effect is related to an estrogen-like effect. This study investigates the potential mechanism of hyperoside's anti-osteoporotic effect by examining its impact on osteoclast differentiation and its relationship with the estrogen receptor. DXA, Micro-CT, TRAP staining, HE, and ELISA were used to assess the impact of hyperoside on OVX-induced osteoporosis. The effect of hyperoside on octeoclast differentiation was evaluated using TRAP activity assay, TRAP staining, F-actin staining. The activation of the estrogen receptor by hyperoside and its relationship with osteoclast differentiation were detected using dual-luciferase reporter assay and estrogen receptor antagonists. Our findings revealed that hyperoside (20-80 mg/kg) protect against OVX-induced osteoporosis, including increasing BMD and BMC and improving bone microstructure. Hyperoside inhibited osteoclast differentiation in a concentration dependent manner, whereas estrogen receptor α antagonists reversed its inhibitory effect osteoclast differentiation. Western blot results suggested that hyperoside inhibited TRAP, RANKL, c-Fos and ITG ß3 protein expression in osteoclast or femoral bone marrow of ovariectomized mice. Our findings suggest that hyperoside inhibits osteoclast differentiation and protects OVX-induced osteoporosis through the ERα/ITGß3 signaling pathway.


Sujet(s)
Différenciation cellulaire , Récepteur alpha des oestrogènes , Ostéoclastes , Ostéoporose , Ovariectomie , Quercétine , Transduction du signal , Animaux , Ovariectomie/effets indésirables , Femelle , Transduction du signal/effets des médicaments et des substances chimiques , Souris , Récepteur alpha des oestrogènes/métabolisme , Quercétine/pharmacologie , Quercétine/analogues et dérivés , Quercétine/usage thérapeutique , Ostéoclastes/effets des médicaments et des substances chimiques , Ostéoclastes/métabolisme , Ostéoporose/traitement médicamenteux , Ostéoporose/métabolisme , Ostéoporose/anatomopathologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Densité osseuse/effets des médicaments et des substances chimiques , Résorption osseuse/traitement médicamenteux , Résorption osseuse/métabolisme , Résorption osseuse/prévention et contrôle
13.
J Pharm Pharmacol ; 76(7): 824-833, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38588462

RÉSUMÉ

We purposed to explore the consequences of the use quercetin and fisetin alone and in combination with pregabalin and gabapentin, which are used in the management of neuropathic pain, and on neuropathic pain in general. The anti-allodynic effect of various doses (5, 10, and 20 mg/kg) of quercetin and fisetin, both singly and in combination with pregabalin and gabapentin, was evaluated by developing a neuropathic pain model induced by chronic constrictive nerve damage in rats. The effectiveness of these flavonoids was investigated by combining them with gabapentin (50 mg/kg) and pregabalin (15 mg/kg), choosing the effectual dose of 10 mg/kg and the dose of 5 mg/kg, which did not show significant antiallodynic effects. In groups combined with gabapentin and pregabalin, it was determined that they showed a significant antiallodynic effect compared with 50 mg/kg gabapentin and 15 mg/kg pregabalin. In conclusion, in our combination studies, it was observed that the effectiveness of gabapentin and pregabalin, was increased and the duration of effect was prolonged when used with lower doses of flavonoids. Based on these findings; it is possible to say that quercetin and fisetin are potential agents that can be used alone or in combination with other effective treatments to alleviate neuropathic pain.


Sujet(s)
Analgésiques , Association de médicaments , Flavonoïdes , Flavonols , Gabapentine , Névralgie , Prégabaline , Quercétine , Acide gamma-amino-butyrique , Prégabaline/administration et posologie , Prégabaline/usage thérapeutique , Gabapentine/administration et posologie , Gabapentine/usage thérapeutique , Gabapentine/pharmacologie , Animaux , Névralgie/traitement médicamenteux , Flavonoïdes/administration et posologie , Flavonoïdes/pharmacologie , Flavonoïdes/usage thérapeutique , Flavonols/pharmacologie , Flavonols/administration et posologie , Flavonols/usage thérapeutique , Mâle , Analgésiques/administration et posologie , Analgésiques/usage thérapeutique , Analgésiques/pharmacologie , Quercétine/administration et posologie , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Rats , Acide gamma-amino-butyrique/administration et posologie , Acide gamma-amino-butyrique/usage thérapeutique , Acide gamma-amino-butyrique/analogues et dérivés , Amines/administration et posologie , Amines/usage thérapeutique , Amines/pharmacologie , Rat Wistar , Relation dose-effet des médicaments , Modèles animaux de maladie humaine , Acides cyclohexanecarboxyliques/administration et posologie , Acides cyclohexanecarboxyliques/usage thérapeutique , Hyperalgésie/traitement médicamenteux
14.
Chem Biol Drug Des ; 103(4): e14520, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38570710

RÉSUMÉ

Quercetin, a bioactive natural compound renowned for its potent anti-inflammatory, antioxidant, and antiviral properties, has exhibited therapeutic potential in various diseases. Given that bronchopulmonary dysplasia (BPD) development is closely linked to inflammation and oxidative stress, and quercetin, a robust antioxidant known to activate NRF2 and influence the ferroptosis pathway, offers promise for a wide range of age groups. Nonetheless, the specific role of quercetin in BPD remains largely unexplored. This study aims to uncover the target role of quercetin in BPD through a combination of network pharmacology, molecular docking, computer analyses, and experimental evaluations.


Sujet(s)
Dysplasie bronchopulmonaire , Ferroptose , Hyperoxie , Animaux , Nouveau-né , Humains , Dysplasie bronchopulmonaire/traitement médicamenteux , Dysplasie bronchopulmonaire/métabolisme , Hyperoxie/traitement médicamenteux , Hyperoxie/métabolisme , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Simulation de docking moléculaire , Cyclooxygenase 2 , Animaux nouveau-nés , Antioxydants , Pharmacologie des réseaux
15.
Phytother Res ; 38(6): 2993-3019, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38600725

RÉSUMÉ

Neurodegenerative disorders (NDs) are among the most common causes of death across the globe. NDs are characterized by progressive damage to CNS neurons, leading to defects in specific brain functions such as memory, cognition, and movement. The most common NDs are Parkinson's, Alzheimer's, Huntington's, and amyotrophic lateral sclerosis (ALS). Despite extensive research, no therapeutics or medications against NDs have been proven to be effective. The current treatment of NDs involving symptom-based targeting of the disease pathogenesis has certain limitations, such as drug resistance, adverse side effects, poor blood-brain barrier permeability, and poor bioavailability of drugs. Some studies have shown that plant-derived natural compounds hold tremendous promise for treating and preventing NDs. Therefore, the primary objective of this review article is to critically analyze the properties and potency of some of the most studied phytomedicines, such as quercetin, curcumin, epigallocatechin gallate (EGCG), apigenin, and cannabinoids, and highlight their advantages and limitations for developing next-generation alternative treatments against NDs. Further extensive research on pre-clinical and clinical studies for developing plant-based drugs against NDs from bench to bedside is warranted.


Sujet(s)
Catéchine , Maladies neurodégénératives , Phytothérapie , Humains , Maladies neurodégénératives/traitement médicamenteux , Catéchine/analogues et dérivés , Catéchine/usage thérapeutique , Catéchine/pharmacologie , Curcumine/usage thérapeutique , Curcumine/pharmacologie , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Animaux , Cannabinoïdes/usage thérapeutique , Cannabinoïdes/pharmacologie , Apigénine/pharmacologie , Apigénine/usage thérapeutique , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Composés phytochimiques/pharmacologie , Composés phytochimiques/usage thérapeutique , Extraits de plantes/usage thérapeutique , Extraits de plantes/pharmacologie
16.
Curr Osteoporos Rep ; 22(3): 353-365, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38652430

RÉSUMÉ

PURPOSE OF REVIEW: This review aims to provide a theoretical basis and insights for quercetin's clinical application in the prevention and treatment of osteoporosis (OP), analyzing its roles in bone formation promotion, bone resorption inhibition, anti-inflammation, antioxidant effects, and potential mechanisms. RECENT FINDINGS: OP, a prevalent bone disorder, is marked by reduced bone mineral density and impaired bone architecture, elevating the risk of fractures in patients. The primary approach to OP management is pharmacotherapy, with quercetin, a phytochemical compound, emerging as a focus of recent interest. This natural flavonoid exerts regulatory effects on bone marrow mesenchymal stem cells, osteoblasts, and osteoclasts and promotes bone health and metabolic equilibrium via anti-inflammatory and antioxidative pathways. Although quercetin has demonstrated significant potential in regulating bone metabolism, there is a need for further high-quality clinical studies focused on medicinal quercetin.


Sujet(s)
Antioxydants , Ostéoporose , Quercétine , Quercétine/usage thérapeutique , Quercétine/pharmacologie , Humains , Ostéoporose/traitement médicamenteux , Antioxydants/usage thérapeutique , Antioxydants/pharmacologie , Ostéoclastes/effets des médicaments et des substances chimiques , Ostéogenèse/effets des médicaments et des substances chimiques , Densité osseuse/effets des médicaments et des substances chimiques , Anti-inflammatoires/usage thérapeutique , Résorption osseuse/traitement médicamenteux , Ostéoblastes/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses , Agents de maintien de la densité osseuse/usage thérapeutique , Agents de maintien de la densité osseuse/pharmacologie
17.
Drug Discov Ther ; 18(2): 117-129, 2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38644207

RÉSUMÉ

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder characterized by a complex pathogenesis and limited treatment options. Yishen Huatan and Huoxue decoction (YHHD), as a traditional Chinese Medicine formula, has shown effectiveness in treating PCOS. However, the specific mechanisms by which YHHD exerts its therapeutic effects remain unclear. In this study, we performed to investigate the therapeutic effects of YHHD and quercetin on dehydroepiandrosterone-induced PCOS mice, and examine the effect of quercetin on the decidualization of T-HESCs under hyperinsulinemic conditions. The results showed that YHHD could reduce early miscarriage rates in PCOS patients and significantly improved glucose metabolism disorders, sex hormone levels, and the estrous cycles in PCOS mice. Quercetin could alleviate effect of high insulin levels and restore the low expression of insulin receptor substrate1/2 (IRS1/2) and glucose transporte 4 (GLUT4) in T-HESCs, demonstrating its potential to mitigate hyperinsulin-induced decidualization dysfunction via the GLUT4 signaling pathway mediated by IRS1/2. This study provides valuable molecular insights of YHHD and highlight the therapeutic potential of quercetin in treating decidualization dysfunction in PCOS.


Sujet(s)
Médicaments issus de plantes chinoises , Syndrome des ovaires polykystiques , Quercétine , Syndrome des ovaires polykystiques/traitement médicamenteux , Syndrome des ovaires polykystiques/métabolisme , Femelle , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Animaux , Médicaments issus de plantes chinoises/pharmacologie , Médicaments issus de plantes chinoises/usage thérapeutique , Souris , Humains , Modèles animaux de maladie humaine , Transporteur de glucose de type 4/métabolisme , Substrats du récepteur à l'insuline/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Adulte , Avortement spontané/traitement médicamenteux , Insuline/sang , Insuline/métabolisme , Déhydroépiandrostérone/pharmacologie , Caduques/effets des médicaments et des substances chimiques , Caduques/métabolisme , Cycle oestral/effets des médicaments et des substances chimiques , Grossesse
18.
BMC Vet Res ; 20(1): 134, 2024 Apr 03.
Article de Anglais | MEDLINE | ID: mdl-38570774

RÉSUMÉ

BACKGROUND: Porcine acute diarrhea syndrome coronavirus (SADS-CoV) is one of the novel pathogens responsible for piglet diarrhea, contributing to substantial economic losses in the farming sector. The broad host range of SADS-CoV raises concerns regarding its potential for cross-species transmission. Currently, there are no effective means of preventing or treating SADS-CoV infection, underscoring the urgent need for identifying efficient antiviral drugs. This study focuses on evaluating quercetin as an antiviral agent against SADS-CoV. RESULTS: In vitro experiments showed that quercetin inhibited SADS-CoV proliferation in a concentration-dependent manner, targeting the adsorption and replication stages of the viral life cycle. Furthermore, quercetin disrupts the regulation of the P53 gene by the virus and inhibits host cell cycle progression induced by SADS-CoV infection. In vivo experiments revealed that quercetin effectively alleviated the clinical symptoms and intestinal pathological damage caused by SADS-CoV-infected piglets, leading to reduced expression levels of inflammatory factors such as TLR3, IL-6, IL-8, and TNF-α. CONCLUSIONS: Therefore, this study provides compelling evidence that quercetin has great potential and promising applications for anti- SADS-CoV action.


Sujet(s)
Alphacoronavirus , Infections à coronavirus , Coronavirus , Maladies des porcs , Suidae , Animaux , Coronavirus/génétique , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Infections à coronavirus/traitement médicamenteux , Infections à coronavirus/médecine vétérinaire , Diarrhée/médecine vétérinaire , Maladies des porcs/traitement médicamenteux
19.
Parasitol Res ; 123(4): 185, 2024 Apr 18.
Article de Anglais | MEDLINE | ID: mdl-38632113

RÉSUMÉ

Leishmania braziliensis (L. braziliensis) causes cutaneous leishmaniasis (CL) in the New World. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administer. Topical treatment would be the ideal option for the treatment of CL. This underscores the urgent need for affordable and effective treatments, with natural compounds being explored as potential solutions. The alkaloid piperine (PIP), the polyphenol curcumin (CUR), and the flavonoid quercetin (QUE), known for their diverse biological properties, are promising candidates to address these parasitic diseases. Initially, the in vitro cytotoxicity activity of the compounds was evaluated using U-937 cells, followed by the assessment of the leishmanicidal activity of these compounds against amastigotes of L. braziliensis. Subsequently, a golden hamster model with stationary-phase L. braziliensis promastigote infections was employed. Once the ulcer appeared, hamsters were treated with QUE, PIP, or CUR formulations and compared to the control group treated with meglumine antimoniate administered intralesionally. We observed that the three organic compounds showed high in vitro leishmanicidal activity with effective concentrations of less than 50 mM, with PIP having the highest activity at a concentration of 8 mM. None of the compounds showed cytotoxic activity for U937 macrophages with values between 500 and 700 mM. In vivo, topical treatment with QUE daily for 15 days produced cured in 100% of hamsters while the effectiveness of CUR and PIP was 83% and 67%, respectively. No failures were observed with QUE. Collectively, our data suggest that topical formulations mainly for QUE but also for CUR and PIP could be a promising topical treatment for CL. Not only the ease of obtaining or synthesizing the organic compounds evaluated in this work but also their commercial availability eliminates one of the most important barriers or bottlenecks in drug development, thus facilitating the roadmap for the development of a topical drug for the management of CL caused by L. braziliensis.


Sujet(s)
Alcaloïdes , Antiprotozoaires , Benzodioxoles , Curcumine , Leishmania brasiliensis , Leishmaniose cutanée , Pipéridines , Amides gras polyinsaturés N-alkylés , Cricetinae , Animaux , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Curcumine/pharmacologie , Leishmaniose cutanée/parasitologie , Alcaloïdes/pharmacologie , Alcaloïdes/usage thérapeutique , Mesocricetus , Antiprotozoaires/pharmacologie
20.
Int J Mol Sci ; 25(8)2024 Apr 19.
Article de Anglais | MEDLINE | ID: mdl-38674092

RÉSUMÉ

Malignant tumors are the second most common cause of death worldwide. More attention is being paid to the link between the body's impaired oxidoreductive balance and cancer incidence. Much attention is being paid to polyphenols derived from plants, as one of their properties is an antioxidant character: the ability to eliminate reactive oxygen and nitrogen species, chelate specific metal ions, modulate signaling pathways affecting inflammation, and raise the level and activity of antioxidant enzymes while lowering those with oxidative effects. The following three compounds, resveratrol, quercetin, and curcumin, are polyphenols modulating multiple molecular targets, or increasing pro-apoptotic protein expression levels and decreasing anti-apoptotic protein expression levels. Experiments conducted in vitro and in vivo on animals and humans suggest using them as chemopreventive agents based on antioxidant properties. The advantage of these natural polyphenols is low toxicity and weak adverse effects at higher doses. However, the compounds discussed are characterized by low bioavailability and solubility, which may make achieving the blood concentrations needed for the desired effect challenging. The solution may lie in derivatives of naturally occurring polyphenols subjected to structural modifications that enhance their beneficial effects or work on implementing new ways of delivering antioxidants that improve their solubility and bioavailability.


Sujet(s)
Antioxydants , Curcumine , Quercétine , Resvératrol , Quercétine/pharmacologie , Quercétine/usage thérapeutique , Quercétine/composition chimique , Curcumine/pharmacologie , Curcumine/usage thérapeutique , Resvératrol/pharmacologie , Humains , Animaux , Antioxydants/pharmacologie , Tumeurs/prévention et contrôle , Tumeurs/traitement médicamenteux , Tumeurs/métabolisme , Chimioprévention/méthodes , Antinéoplasiques/pharmacologie , Polyphénols/pharmacologie , Polyphénols/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...